76 related articles for article (PubMed ID: 8121779)
1. [Clinical application of AMI-25 (superparamagnetic iron oxide) for the MR imaging of hepatic tumors: a multicenter clinical phase III study].
Yoshikawa K; Sasaki Y; Ogawa N; Sakuma S
Nihon Igaku Hoshasen Gakkai Zasshi; 1994 Feb; 54(2):137-53. PubMed ID: 8121779
[TBL] [Abstract][Full Text] [Related]
2. Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
Saini S; Edelman RR; Sharma P; Li W; Mayo-Smith W; Slater GJ; Eisenberg PJ; Hahn PF
AJR Am J Roentgenol; 1995 May; 164(5):1147-52. PubMed ID: 7717222
[TBL] [Abstract][Full Text] [Related]
3. [The MR tomography of focal liver lesions with the superparamagnetic contrast agent AMI-25 at 1.5 tesla].
Duda SH; Laniado M; Kopp AF; Grönewäller E; Aicher KP; Pavone P; Jehle E; Claussen CD
Rofo; 1994 Jan; 160(1):46-51. PubMed ID: 8305692
[TBL] [Abstract][Full Text] [Related]
4. Hepatic tumors: detection and characterization at 1-T MR imaging enhanced with AMI-25.
Denys A; Arrive L; Servois V; Dubray B; Najmark D; Sibert A; Menu Y
Radiology; 1994 Dec; 193(3):665-9. PubMed ID: 7972805
[TBL] [Abstract][Full Text] [Related]
5. [Three-dimensional MR angiography of HCC and portal and hepatic veins using superparamagnetic iron oxide].
Ono Y; Marukawa T; Ashikaga R; Inoue M; Fujii K; Araki Y; Ishida O
Nihon Igaku Hoshasen Gakkai Zasshi; 1998 Feb; 58(3):97-8. PubMed ID: 9558852
[TBL] [Abstract][Full Text] [Related]
6. European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients.
Chachuat A; Bonnemain B
Radiologe; 1995 Nov; 35(11 Suppl 2):S274-6. PubMed ID: 8588035
[No Abstract] [Full Text] [Related]
7. [Detection of liver lesions: magnetic resonance tomography using superparamagnetic iron particles (AMI-25, endorem) as a contrast medium in comparison with ultrasound diagnosis, computerized tomography and CT portography].
Pleger B; Beyer HK; Laufer U
Rontgenpraxis; 2001; 53(6):245-9. PubMed ID: 11402872
[No Abstract] [Full Text] [Related]
8. MR enhancement of hepatoma by superparamagnetic iron oxide (SPIO) particles.
Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Takahashi M
J Comput Assist Tomogr; 1995; 19(4):665-7. PubMed ID: 7622710
[No Abstract] [Full Text] [Related]
9. [The endorem tolerance profile].
Laniado M; Chachuat A
Radiologe; 1995 Nov; 35(11 Suppl 2):S266-70. PubMed ID: 8588033
[TBL] [Abstract][Full Text] [Related]
10. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging.
Bellin MF; Zaim S; Auberton E; Sarfati G; Duron JJ; Khayat D; Grellet J
Radiology; 1994 Dec; 193(3):657-63. PubMed ID: 7972804
[TBL] [Abstract][Full Text] [Related]
11. [MR contrast agent: resovist (SH U 555A)].
Nakajima H; Ichikawa T
Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
[No Abstract] [Full Text] [Related]
12. Benign hepatocellular tumors: MRI after superparamagnetic iron oxide administration.
Grandin C; Van Beers BE; Robert A; Gigot JF; Geubel A; Pringot J
J Comput Assist Tomogr; 1995; 19(3):412-8. PubMed ID: 7790551
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance imaging of hepatocellular carcinoma using contrast media.
Kim MJ; Choi JY; Chung YE; Choi SY
Oncology; 2008; 75 Suppl 1():72-82. PubMed ID: 19092275
[TBL] [Abstract][Full Text] [Related]
14. Liver MR imaging with iron oxides: toward consensus and clinical practice.
Weissleder R
Radiology; 1994 Dec; 193(3):593-5. PubMed ID: 7972790
[No Abstract] [Full Text] [Related]
15. Clinical evaluation of ultrasmall superparamagnetic iron oxide particles for liver imaging.
Saini S; Edelman RR; Li W; Petersein J; Hahn PF
Acad Radiol; 1996 Aug; 3 Suppl 2():S409-12. PubMed ID: 8796616
[No Abstract] [Full Text] [Related]
16. Hepatic MR imaging with ferumoxides: a multicenter clinical trial of the safety and efficacy in the detection of focal hepatic lesions.
Ros PR; Freeny PC; Harms SE; Seltzer SE; Davis PL; Chan TW; Stillman AE; Muroff LR; Runge VM; Nissenbaum MA
Radiology; 1995 Aug; 196(2):481-8. PubMed ID: 7617864
[TBL] [Abstract][Full Text] [Related]
17. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review.
Petersein J; Saini S; Weissleder R
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):53-60. PubMed ID: 8673716
[TBL] [Abstract][Full Text] [Related]
18. MR imaging with i.v. superparamagnetic iron oxide: efficacy in the detection of focal hepatic lesions.
Winter TC; Freeny PC; Nghiem HV; Mack LA; Patten RM; Thomas CR; Elliott S
AJR Am J Roentgenol; 1993 Dec; 161(6):1191-8. PubMed ID: 8249724
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging.
Yamamoto H; Yamashita Y; Yoshimatsu S; Baba Y; Hatanaka Y; Murakami R; Nishiharu T; Takahashi M; Higashida Y; Moribe N
Radiology; 1995 Apr; 195(1):106-12. PubMed ID: 7892448
[TBL] [Abstract][Full Text] [Related]
20. Tumor-detecting capacity and clinical usefulness of SPIO-MRI in patients with hepatocellular carcinoma.
Nakamura H; Ito N; Kotake F; Mizokami Y; Matsuoka T
J Gastroenterol; 2000; 35(11):849-55. PubMed ID: 11085494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
